Highlights:

  • AVITA Medical reported Q1 2026 total Revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, with contributions from Cohealyx and improved RECELL utilisation as reimbursement dynamics normalise following prior-period disruption.
  • The company secured a 10-year BARDA agreement valued at up to $25.5 million to support U.S. burn emergency preparedness, providing recurring readiness revenue and a significant commercial validation of AVITA's technology in a government procurement context.
  • Cary Vance was appointed as President and Chief Executive Officer following a comprehensive search led by a special committee of the Board of Directors, with Jan Stern Reed appointed as independent Chair — a governance reset designed to support the company's next phase of strategic execution.

 

AVITA Medical Inc. (Nasdaq:RCEL) (ASX:AVH), a therapeutic acute wound care company focused on transformative skin regeneration solutions, reported its first quarter 2026 financial results on 14 May 2026, presenting a picture of gradual recovery across key commercial metrics even as the company navigates a period of management transition and operating cost restructuring. AVH shares were trading at AUD 1.22 on 15 May, up 1.67% on the day, though the stock has declined approximately 42.18% over the past twelve months — a trajectory that reflects the challenges the company has faced in scaling its commercial operations and achieving profitability.

Q1 2026 total revenue of approximately $19.3 million represents 4% growth year-over-year and a more meaningful 10% sequential improvement from Q4 2025. The sequential acceleration is particularly noteworthy, driven by contributions from Cohealyx — the company's newer wound care product — alongside improved RECELL utilisation as the reimbursement environment normalises following the dynamics that weighed on performance in prior periods. These are positive directional signals, though the company's net loss of $10.6 million for the quarter underscores that the path to profitability remains a work in progress.

RECELL and Cohealyx: The Commercial Engine

RECELL is AVITA Medical's flagship product — a point-of-care skin cell harvesting and spraying system used primarily in burn wound treatment that enables rapid skin regeneration from small donor sites. The product has established clinical credentials and reimbursement coverage in the United States for acute burns, and its utilisation trajectory in Q1 2026 reflects stabilisation following a period in which reimbursement policy changes created uncertainty for hospital purchasing decisions. Management's reference to reimbursement dynamics 'normalising' suggests that the headwinds from that period are progressively abating, creating a more stable commercial foundation.

Cohealyx, AVITA's newer product, is a commercially significant addition to the portfolio in two respects. First, it represents product Diversification beyond the RECELL core, expanding the company's addressable patient population and revenue streams. Second, the Q1 2026 announcement includes reference to positive interim Cohealyx I data demonstrating approximately a 20-day reduction in mean time to skin grafting readiness — 13.6 days versus 33.2 days. This clinical data point, if confirmed in final trial results, would represent a compelling clinical differentiation that could support broader adoption across burn and wound care centres.

Gross Margin and Operating Cost Discipline

AVITA Medical's Gross Profit Margin of 81.7% in Q1 2026 is a notable feature of the financial results, even accounting for the impact of product mix and certain inventory adjustments noted by management. Gross margins above 80% are characteristic of high-value medical device and Biologics businesses, and AVITA's margin profile reflects the proprietary nature of its technology and the premium positioning of its products in the wound care market. The slight pressure from product mix and inventory adjustments is a manageable item rather than a structural concern.

The more meaningful operating story is on the cost side. Operating expenses decreased 11% year-over-year to $24.5 million in Q1 2026, reflecting the lower and more disciplined cost base that management established during 2025. This cost reduction, achieved without corresponding revenue growth of equal magnitude, represents a genuine structural improvement in the company's Operating Leverage profile. As revenue continues to grow — particularly if Cohealyx and improved RECELL utilisation continue to compound — the combination of high gross margins and a more disciplined Fixed Cost base creates a pathway toward meaningful operating leverage improvements.

BARDA Agreement: Government Validation and Recurring Revenue

Among the most strategically significant developments in Q1 2026 is the execution of a 10-year BARDA (Biomedical Advanced Research and Development Authority) agreement valued at up to $25.5 million to support U.S. burn emergency preparedness. BARDA is an agency within the U.S. Department of Health and Human Services responsible for advanced development of medical countermeasures against chemical, biological, radiological, nuclear, and emerging infectious disease threats. A 10-year engagement for burn emergency preparedness provides AVITA with a long-duration government revenue stream that is largely independent of commercial reimbursement dynamics.

The BARDA agreement is also a powerful validation signal. Government defence and emergency preparedness agencies subject potential partners to rigorous Due Diligence before entering multi-year commitments, and the award of a 10-year contract signals official confidence in AVITA's technology, Manufacturing capability, and organisational reliability. This type of government endorsement can catalyse confidence among hospital procurement decision-makers and potentially accelerate commercial adoption of RECELL in emergency and trauma settings.

Leadership Change and Governance Reset

The appointment of Cary Vance as President and CEO following a comprehensive board-led search represents a deliberate governance reset for AVITA Medical. Alongside the appointment of Jan Stern Reed as independent Chair, the leadership changes signal that the board is committed to providing the company with experienced, focused management to execute the next phase of commercial growth. The search process — described as comprehensive and led by a special committee — suggests a rigorous approach to finding leadership capable of addressing both the near-term commercial execution challenges and the longer-term strategic opportunities.

Cash Management and Near-Term Outlook

Net cash use of approximately $9.9 million in Q1 2026 was influenced by one-time items and the timing of revenue collections, with management guiding that cash use is expected to decrease significantly in Q2 2026. This guidance is important context for investors tracking AVITA's cash runway and Burn Rate, and the expected improvement in Q2 cash use suggests that Q1's figure overstates the underlying quarterly cash consumption rate. The company's cash management discipline will be a key variable for the market in coming quarters as it assesses the pace of the company's progress toward Operating Cash Flow breakeven.

Conclusion

AVITA Medical's Q1 2026 results present a company making measured progress in a challenging operating environment. Sequential revenue growth of 10%, an 81.7% gross margin, an 11% reduction in operating expenses, a landmark BARDA agreement, positive Cohealyx clinical data, and a leadership reset all represent constructive developments. The persistence of the net loss and the share price's 42% decline over the past year reflect the market's ongoing scrutiny of the company's timeline to profitability. The trajectory of reimbursement normalisation, Cohealyx commercialisation, and BARDA revenue recognition will be the key indicators for investors tracking AVITA's recovery.